Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | HTR2C | P28335 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HTR1D | P28221 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | MARK3 | P27448 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778860 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL7460028 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL6631651 | 0.83 | KDM4E (0.70) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL2783986 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL3836149 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| Water SCHEMBL10867618 | 0.82 | HTR6 (0.70) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL4880407 | 0.81 | HTR6 (1.00) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL6631360 | 0.80 | HTR6 (0.60) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL13533314 | 0.80 | HTR6 (0.63) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| Hydrochloric Acid SCHEMBL11261885 | 0.80 | HTR6 (0.65) | HTR6KDM4EALDH1A1HSD17B10HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| CN-103122001-A | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL | 2013-05-29 | — | — | CN | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| CN-101917995-A | POLO-like kinase inhibitors | TAKEDA PHARMACEUTICAL | 2010-12-15 | — | — | CN | disclosed |
| EP-2205241-A1 | POLO-LIKE KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-5962473-A | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962474-A | ANALGESICS; HEADACHES | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| CN-1184425-A | 5-substituted-3- (1,2,3, 6-tetrahydropyridin-4-yl) -and 3- (piperidin-4-yl) -1H-indoles, 5-HT1FAgonists | LILLY CO ELI (US) | 1998-06-10 | — | — | CN | disclosed |
| EP-0832650-A2 | Use of serotonin 5-HT1F agonists for the prevention of migraine | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998011895-A1 | A METHOD FOR THE PREVENTION OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | disclosed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5708008-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1997000244-A1 | PROCESS FOR PARALLEL SYNTHESIS OF A NON-PEPTIDE LIBRARY | ELI LILLY AND COMPANY (US) | 1997-01-03 | — | — | WO | disclosed |
| WO-1996029075-A1 | 5-SUBSTITUTED-3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)- AND 3-(PIPERIDIN-4-YL)-1H-INDOLES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0733628-A1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | HTR6 4477/4885KDM4E 2195/4885ALDH1A1 4009/4885 |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | HTR6 4477/4885KDM4E 2195/4885ALDH1A1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.